SIMCERE PHARMA(02096)

7.790-0.310-3.83%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Simcere Pharmaceutical Group Gets NDA for Anti-Influenza from NMPA
  MT Newswires Live · 03-17
  Simcere Pharmaceutical Group Gets NDA for Anti-Influenza from NMPA
- BRIEF-Simcere Pharmaceutical Says NDA Of Deunoxavir Marboxil Tablets Accepted By NMPA
  Reuters · 03-17
  BRIEF-Simcere Pharmaceutical Says NDA Of Deunoxavir Marboxil Tablets Accepted By NMPA
- Simcere Pharmaceutical - New Drug Application (Nda) of Deunoxavir Marboxil Tablets Was Accepted by Nmpa
  THOMSON REUTERS · 03-16
  Simcere Pharmaceutical - New Drug Application (Nda) of Deunoxavir Marboxil Tablets Was Accepted by Nmpa
- Simcere Pharmaceutical Group Limited's (HKG:2096) Price In Tune With Revenues
  Simply Wall St. · 03-06
  Simcere Pharmaceutical Group Limited's (HKG:2096) Price In Tune With Revenues
- Simcere Pharmaceutical Forecasts Slight Increase in 2024 Profit
  MT Newswires Live · 02-21
  Simcere Pharmaceutical Forecasts Slight Increase in 2024 Profit
- Fermion and Simcere Enter Into an Exclusive License and Collaboration Agreement for China's First Sstr4 Agonist Targeting Pain
  THOMSON REUTERS · 01-18
  Fermion and Simcere Enter Into an Exclusive License and Collaboration Agreement for China's First Sstr4 Agonist Targeting Pain
- BRIEF-Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie
  Reuters · 01-13
  BRIEF-Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie
- China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate
  Reuters · 01-13
  China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate
- Simcere Zaiming and Abbvie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
  THOMSON REUTERS · 01-13
  Simcere Zaiming and Abbvie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
- Abbvie Inc - Simcere Zaiming to Receive up to $1.055B in Payments From Abbvie
  THOMSON REUTERS · 01-13
  Abbvie Inc - Simcere Zaiming to Receive up to $1.055B in Payments From Abbvie
- Abbvie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
  THOMSON REUTERS · 01-13
  Abbvie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
- Abbvie Inc - Eligible to Receive Tiered Royalties on Sales in Greater China
  THOMSON REUTERS · 01-13
  Abbvie Inc - Eligible to Receive Tiered Royalties on Sales in Greater China
- Simcere Pharmaceutical - - Option to License Agreement of Sim0500 With Abbvie for Rights Outside Greater China
  THOMSON REUTERS · 01-13
  Simcere Pharmaceutical - - Option to License Agreement of Sim0500 With Abbvie for Rights Outside Greater China
- Simcere Pharmaceutical- Under Deal Co to Receive Upfront Payment From Abbvie, Eligible to Receive Option Fees & Milestone Payments of up to $1.055 Bln
  THOMSON REUTERS · 01-13
  Simcere Pharmaceutical- Under Deal Co to Receive Upfront Payment From Abbvie, Eligible to Receive Option Fees & Milestone Payments of up to $1.055 Bln
- Simcere Pharma Gets Clinical Trial Nod in China for Anti-Tumor Drug
  MT Newswires Live · 01-06
  Simcere Pharma Gets Clinical Trial Nod in China for Anti-Tumor Drug
- BRIEF-Simcere Pharmaceutical Says Clinical Trial Approval For SIM0505 Issued By NMPA
  Reuters · 01-06
  BRIEF-Simcere Pharmaceutical Says Clinical Trial Approval For SIM0505 Issued By NMPA
- Simcere Pharmaceutical - Clinical Trial Approval for Sim0505 Issued by Nmpa
  THOMSON REUTERS · 01-06
  Simcere Pharmaceutical - Clinical Trial Approval for Sim0505 Issued by Nmpa
- Simcere Pharmaceutical Group Renews Key Agreements
  MT Newswires Live · 2024-12-24
  Simcere Pharmaceutical Group Renews Key Agreements
- China Nmpa Approves Simcere's Sanbexin® Sublingual Tablets for the Treatment of Acute Ischemic Stroke
  THOMSON REUTERS · 2024-12-04
  China Nmpa Approves Simcere's Sanbexin® Sublingual Tablets for the Treatment of Acute Ischemic Stroke
- Simcere Pharmaceutical Group's AIS-Related Drug Gets Marketing Approval in China
  MT Newswires Live · 2024-12-02
  Simcere Pharmaceutical Group's AIS-Related Drug Gets Marketing Approval in China
Company Profile
Company Name
SIMCERE PHARMA
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.simcere.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces various drugs, including Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions. The Company mainly conducts its businesses in the domestic market and overseas markets.

1D
5D
Day
Week
Month

High

8.100

Open

8.100

Volume%

1.14

Low

7.750

8.100

T/O Rate

0.21%

抱歉，当前请求异常(-1)

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

SIMCERE PHARMA(02096)

Company Profile